UP!

AGIO $38.28   View long term graphs

Agios Pharmaceuticals, Inc.
Type
Public
Traded as NASDAQ: AGIO
Industry Pharmaceuticals
Founded 2008 (2008)
Headquarters Cambridge, Massachusetts, United States
Key people
David Schenkein (CEO)
Website agios.com
Footnotes / references
Foundation

Agios Pharmaceuticals is a public American pharmaceutical company focused on developing small-molecule anti-cancer therapeutics targeting cancer cell metabolism via the growth factor pathway. Among the proteins under investigation by the company are IDH1 and IDH2. The company was founded in 2008 (or 2007) by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.

In 2012, Agios was named among the defendants in a lawsuit against one of its founders, Craig Thompson, alleging that Thompson used research illegally taken from the Abramson Family Cancer Research Institute in research at Agios.

In May 2016, the company announced it would launch partnership with Celgene, developing metabolic immuno-oncology therapies. The deal could net more than $1 billion for Agios.

In April 2017, the company raised $250 million in a new stock offering in anticipation of FDA approval for its first cancer drug.

As of April 2017, Agios' CEO was David Schenkein.

Agios was established as a private company and converted to a public company with its initial public offering in July 2013 and subsequent listing on NASDAQ.


Q reports

Period Date Adjusted Actuals EPS GAAP EPS
Q4 2020 2021-02-11 Future report Set alerts
Q3 2020 2020-10-29 Future report Set alerts
Q2 2020 2020-07-30 -1.31 -1.31
Q1 2020 2020-04-30 -0.59 -0.59
Q4 2019 2020-02-13 -1.60 -1.60
Q3 2019 2019-10-31 -1.81 -1.81
Q2 2019 2019-08-01 -1.87 -1.87
Q1 2019 2019-05-02 -1.59 -1.59
Q4 2018 2019-02-14 -1.58 -1.58
Q3 2018 2018-11-01 -1.63 -1.63

Ratings

2016-06-13 Reiterated Rating Goldman Sachs Hold $46.00
2016-06-13 Reiterated Rating Janney Montgomery Scott Neutral $52.00 to $47.00
2016-06-13 Upgrade JPMorgan Chase & Co. Neutral to Overweight $50.00 to $62.00
2016-06-13 Upgrade Canaccord Genuity Hold to Buy $50.00 to $90.00
2016-06-13 Reiterated Rating Goldman Sachs Group Inc. Hold $46.00
2016-06-10 Reiterated Rating JPMorgan Chase & Co. Hold
2016-06-09 Reiterated Rating Canaccord Genuity Hold $50.00
2016-05-24 Reiterated Rating Cowen and Company Buy
2016-05-19 Reiterated Rating Leerink Swann Market Perform $56.00
2016-05-18 Reiterated Rating Canaccord Genuity Hold $50.00
2016-05-18 Boost Price Target Credit Suisse Outperform $65.00 to $70.00
2016-05-18 Boost Price Target SunTrust Buy $57.00 to $65.00
2016-05-18 Reiterated Rating Cowen and Company Buy
2016-05-18 Boost Price Target Credit Suisse Group AG Outperform $65.00 to $70.00
2016-05-18 Boost Price Target SunTrust Banks Inc. Buy $57.00 to $65.00
2016-04-25 Reiterated Rating Credit Suisse Buy
2016-03-31 Reiterated Rating JPMorgan Chase & Co. Hold
2016-03-29 Initiated Coverage SunTrust Buy $57.00
2016-03-27 Reiterated Rating Credit Suisse Buy
2016-03-04 Reiterated Rating Canaccord Genuity Hold $70.00 to $50.00
2016-03-01 Initiated Coverage Janney Montgomery Scott Neutral $43.00
2016-02-22 Lower Price Target Goldman Sachs $72.00 to $47.00
2016-02-19 Reiterated Rating Leerink Swann Market Perform $62.00 to $56.00
2016-02-19 Lower Price Target Credit Suisse $75.00 to $66.00
2016-01-20 Initiated Coverage Credit Suisse Outperform $75.00
2015-12-07 Downgrade Leerink Swann Outperform to Market Perform $105.00 to $62.00
2015-11-09 Lower Price Target Roth Capital Neutral $114.00 to $75.00
2015-11-09 Reiterated Rating Oppenheimer Hold
2015-11-09 Reiterated Rating Oppenheimer Holdings Inc. Hold
2015-10-26 Lower Price Target Leerink Swann Outperform $124.00 to $105.00
2015-10-21 Reiterated Rating Oppenheimer Market Perform
2015-10-15 Reiterated Rating Canaccord Genuity Hold $93.00 to $70.00
2015-08-07 Reiterated Rating Canaccord Genuity Hold $93.00
2015-08-05 Reiterated Rating Roth Capital Hold $114.00
2015-07-22 Initiated Coverage Northland Securities Outperform $132.00
2015-07-02 Upgrade Desjardins Hold to Buy
2015-06-15 Lower Price Target Canaccord Genuity Hold $103.00 to $93.00
2015-06-02 Initiated Coverage Citigroup Inc. Neutral $132.00
2015-05-08 Initiated Coverage MLV & Co. Buy $130.00
2015-04-30 Downgrade Canaccord Genuity Buy to Hold $163.00 to $103.00
2015-04-20 Initiated Coverage Oppenheimer Market Perform
2015-02-18 Set Price Target Citigroup Inc. Hold $137.00 to $132.00
2015-02-18 Boost Price Target MLV & Co. Buy $123.00 to $130.00
2015-02-17 Set Price Target Canaccord Genuity Buy $163.00
2015-01-28 Downgrade Citigroup Inc. Buy to Neutral $93.00 to $137.00
2015-01-05 Initiated Coverage Roth Capital Neutral $114.00
2014-12-04 Initiated MLV & Co Buy $123
2014-12-04 Initiated Coverage MLV & Co. Buy $123.00
2014-12-02 Downgrade JPMorgan Chase & Co. Overweight to Neutral $60.00 to $90.00
2014-11-19 Reiterated Rating Canaccord Genuity Buy $97.00 to $111.00
2014-11-12 Initiated Coverage Canaccord Genuity Buy $97.00
2014-11-07 Downgrade Goldman Sachs Buy to Neutral
2014-07-01 Initiated Coverage Citigroup Inc. Buy $58.00
2014-06-16 Reiterated Rating JPMorgan Chase & Co. Overweight $55.00 to $60.00
2014-04-07 Boost Price Target Leerink Swann $51.00 to $65.00
2014-04-07 Upgrade JPMorgan Chase & Co. Neutral to Overweight $40.00 to $55.00
2014-03-28 Boost Price Target JPMorgan Chase & Co. $35.00 to $40.00
2014-03-07 Boost Price Target Leerink Swann $38.00 to $51.00
2016-06-13 Reiterated Rating Goldman Sachs Hold $46.00
2016-06-13 Reiterated Rating Janney Montgomery Scott Neutral $52.00 to $47.00
2016-06-13 Upgrade JPMorgan Chase & Co. Neutral to Overweight $50.00 to $62.00
2016-06-13 Upgrade Canaccord Genuity Hold to Buy $50.00 to $90.00
2016-06-13 Reiterated Rating Goldman Sachs Group Inc. Hold $46.00

There is presents forecasts of rating agencies and recommendations for investors about this ticker

Major Shareholders

Name Relationship Total Shares Holding stocks
Arch Venture Fund VII LP 8.96%  (3088590) AGIO / BLUE / JUNO / RCPT / RTGN / SAGE /
Flagship Ventures Fund 2007, L.P. 5.60%  (1930369) AGIO / EBIO / RCPT /
Celgene European Investment Co LLC 5.39%  (1856353) AGIO / CELG / EPZM /
CELGENE CORP /DE/ 3.99%  (1374599) AGIO / ALQA / CELG / XLRN /
STARR KEVIN P 0.54%  (184386) AGIO / ALNY / SAGE /
Higgons John Duncan Chief Operating Officer 0.35%  (120834) AGIO /
Tessier-Lavigne Marc 0.29%  (101009) AGIO / PFE / REGN /
Cantley Lewis Clayton Jr. 0.23%  (79515) AGIO /
Biller Scott Chief Scientific Officer 0.17%  (57196) AGIO /
MARAGANORE JOHN 0.14%  (49764) AGIO / ALNY / BLUE / RGLS /
Goddard Glenn Senior Vice President, Finance 0.03%  (10000) AGIO /
Cole Douglas G. 0.01%  (2778) AGIO / RCPT / TTPH /
Foster-Cheek Kaye I 0.01%  (2200) AGIO /
Alenson Carman Principal Accounting Officer 0.01%  (2150) AGIO /

Comments